Heterogeneous clinical and pathological landscapes of HER2 positive colorectal cancer

References

• Filip S, Vymetalkova V, Petera J, et al. Distant Metastasis in Colorectal Cancer Patients—Do We Have New Predicting Clinicopathological and Molecular Biomarkers? A Comprehensive Review. Int J Mol Sci. 2020;21(15):5255.
   Web of Science ®Google Scholar
• Siegel RL, Miller KD, Sauer AG, et al. Colorectal cancer statistics. CA Cancer J Clin. 2020;70(3):145–164. 2020.
   PubMed Web of Science ®Google Scholar
• Li QH, Wang YZ, Tu J, et al. Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance. Gastroenterol Rep (Oxf). 2020;8(3):179–191.
   PubMed Web of Science ®Google Scholar
• Bertotti A, Migliardi G, Galimi F, et al. A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 2011;1(6):508–523.
   PubMed Web of Science ®Google Scholar
• Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365(14):1273–1283.
   PubMed Web of Science ®Google Scholar
• Boku N. HER2-positive gastric cancer. Gastric Cancer. 2014;17(1):1–12.
   PubMed Web of Science ®Google Scholar
• Olayioye MA, Neve RM, Lane HA, et al. The ErbB signaling network: receptor heterodimerization in development and cancer. Embo J. 2000;19(13):3159–3167.
   PubMed Web of Science ®Google Scholar
• Belli V, Matrone N, Napolitano S, et al. Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models. J Exp Clin Cancer Res. 2019;38(1):1–14.
   PubMedGoogle Scholar
• Stocker A, Trojan A, Elfgen C, et al. Differential prognostic value of positive HER2 status determined by immunohistochemistry or fluorescence in situ hybridization in breast cancer. Breast Cancer Res Treat. 2020;183(2):311–319.
   PubMed Web of Science ®Google Scholar
• Liu F, Ren C, Jin Y, et al. Assessment of two different HER2 scoring systems and clinical relevance for colorectal cancer. Virchows Archiv. 2020;476(3):391–398.
   PubMed Web of Science ®Google Scholar
• Hoda RS, Bowman AS, Zehir AS, et al. Next‐generation assessment of human epidermal growth factor receptor 2 gene (ERBB2) amplification status in invasive breast carcinoma: a focus on Group 4 by use of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 testing guideline. Histopathology 2020;78(4):498–507.
   PubMed Web of Science ®Google Scholar
• Pyo JS, Kang G, Park K. Clinicopathological significance and diagnostic accuracy of HER2 immunohistochemistry in colorectal cancer: a meta-analysis. Int J Biol Markers. 2016;31(4):389–394.
   Web of Science ®Google Scholar
• Wei Q, Zhang YJ, Gao J, et al. Clinicopathologic characteristics of HER2-positive metastatic colorectal cancer and detection of HER2 in plasma circulating tumor DNA. Clin Colorectal Cancer. 2019;18(3):175–182.
   PubMed Web of Science ®Google Scholar
• Sartore-Bianchi A, Trusolino L, Martino C, et al., Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 17(6): 738–746. 2016.
   PubMed Web of Science ®Google Scholar
• Li Q, Wang D, Li J, et al. Clinicopathological and prognostic significance of HER-2/neu and VEGF expression in colon carcinomas. BMC Cancer. 2011;11:277.
   PubMed Web of Science ®Google Scholar
• Tu JH, Yu YH, Wei L, et al. Significance of human epidermal growth factor receptor 2 expression in colorectal cancer. Exp Ther Med. 2015;9(1):17–24.
   PubMed Web of Science ®Google Scholar
• Pappas A, Lagoudianakis E, Seretis C. et al. Clinical role of HER-2/neu expression in colorectal cancer. J BUON. 2013;18(1):98–104.
   PubMed Web of Science ®Google Scholar
• Pahuja KB, Nguyen TT, Jaiswal BS, et al. Actionable Activating Oncogenic ERRB2/HER2 Transmembrane and Juxtamembrane Domain Mutations. Cancer Cell. 2018;34(5):792–806.
   PubMed Web of Science ®Google Scholar
• Kavuri SM, Jain N, Galimi F, et al. HER2 Activating Mutations Are Targets for Colorectal Cancer Treatment. Cancer Discov. 2015;5(8):832–841.
   PubMed Web of Science ®Google Scholar
• Shimada Y, Yagi R, Kameyama H, et al. Utility of comprehensive genomic sequencing for detecting HER2-positive colorectal cancer. Hum Pathol. 2017;66:1–9.
   PubMed Web of Science ®Google Scholar
• Feng Y, Li YQ, Huang D, et al. HER2 as a potential biomarker guiding adjuvant chemotherapy in stage II colorectal cancer. Eur J Surg Oncol. 2019;45(2):167–173.
   PubMed Web of Science ®Google Scholar
• Shan L, Lv YM, Bai BJ, et al. Variability in HER2 expression between primary colorectal cancer and corresponding metastases. J Cancer Res Clin Oncol. 2018;144(11):2275–2281.
   PubMed Web of Science ®Google Scholar
• Heppner BI, Behrens HM, Balschun K, et al. HER2/neu testing in primary colorectal carcinoma. Br J Cancer. 2014;111(10):1977–1984.
   PubMed Web of Science ®Google Scholar
• Sartore‐Bianchi A, Amatu A, Porcu L, et al., HER2 Positivity Predicts Unresponsiveness to EGFR‐Targeted Treatment in Metastatic Colorectal Cancer. Oncologist. 24(10): 1395–1402. 2019.
   PubMed Web of Science ®Google Scholar
• Salem ME, Weinberg BA, Xiu J, et al. Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers. Oncotarget. 2017;8(49):86356–86368.
   PubMedGoogle Scholar
• Hurwitz H, Raghav KPS, Burris HA, et al. Pertuzumab+ trastuzumab for HER2-amplified/overexpressed metastatic colorectal cancer (mCRC): interim data from MyPathway. JCO. 2017;35(4_suppl):676.
   Web of Science ®Google Scholar
• Richman SD, Southward K, Chambers P, et al. HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. J Pathol. 2016;238(4):562–570.
   PubMed Web of Science ®Google Scholar
• Lee WS, Park YH, Lee JN, et al. Comparison of HER2 expression between primary colorectal cancer and their corresponding metastases. Cancer Med. 2014;3(3):674–680.
   PubMed Web of Science ®Google Scholar
• El-Deiry WS, Vijayvergia N, Xiu J, et al. Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites. Cancer Biol Ther. 2016;16(12):1726–1737.
   Web of Science ®Google Scholar
• Conradiv LC, Styczen H, Sprenger T, et al. Frequency of HER-2 positivity in rectal cancer and prognosis. Am J Surg Pathol. 2013;37(4):522–531.
   PubMed Web of Science ®Google Scholar
• Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet. 2014;383(9927):1490–1502.
   PubMed Web of Science ®Google Scholar
• Marx AH, Burandt EC, Choschzick M, et al. Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers. Hum Pathol. 2014;41(11):1577–1585.
   Google Scholar
• Kruszewski WJ, Rzepko R, Ciesielski M, et al. Expression of HER2 in colorectal cancer does not correlate with prognosis. Dis Markers. 2010;29(5):207–212.
   PubMed Web of Science ®Google Scholar
• Li SS, Buchbinder E, Wu LH, et al. EGFR and HER2 levels are frequently elevated in colon cancer cells. Discoveries Reports. 2014;1(1):e1
   Google Scholar
• Khelwatty SA, Essapen S, Seddon AM, et al. Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers. Br J Cancer. 2015;113(7):1010–1019.
   PubMed Web of Science ®Google Scholar
• Zhang L, Castanaro C, Luan B, et al. ERBB3/HER2 signaling promotes resistance to EGFR blockade in head and neck and colorectal cancer models. Mol Cancer Ther. 2014;13(5):1345–1355.
   PubMed Web of Science ®Google Scholar
• Loibl S, Von Minckwitz G, Schneeweiss A, et al. PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer. J Clin Oncol. 2014;32(29):3212–3220.
   PubMed Web of Science ®Google Scholar
• Hanker AB, Pfefferle AD, Balko JM, et al. Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies. Proc Natl Acad Sci USA. 2013;110(35):14372–14377.
   PubMed Web of Science ®Google Scholar
• De Grève J, Teugels E, Geers C, et al. Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. Lung Cancer. 2012;76(1):123–127.
   PubMed Web of Science ®Google Scholar
• Guan SS, Chang JS, Cheng CC, et al. Afatinib and its encapsulated polymeric micelles inhibits HER2-overexpressed colorectal tumor cell growth in vitro and in vivo. Oncotarget 2014;5(13):4868–4880.
   PubMed Web of Science ®Google Scholar
• Kloth M, Ruesseler V, Engel C, et al. Activating ERBB2/HER2 mutations indicate susceptibility to pan-HER inhibitors in Lynch and Lynch-like colorectal cancer. Gut 2016;65(8):1296–1305.
   PubMed Web of Science ®Google Scholar
• Li G, Zheng JH, Xu B, et al. Simvastatin inhibits tumor angiogenesis in HER2-overexpressing human colorectal cancer. Biomed Pharmacother. 2017;85: 418–424
   PubMed Web of Science ®Google Scholar
• Oh D-Y BY. HER2-targeted therapies-a role beyond breast cancer. Nat Rev Clin Oncol. 2020;17(1):33–48.
   PubMed Web of Science ®Google Scholar
• Meric-Bernstam F, Hurwitz H, Raghav KPS, et al., Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 20(4): 518–530. 2019.
   PubMed Web of Science ®Google Scholar
• Benson AB, Venook AP, Al-Hawary MM, et al.NCCN guidelines insights: rectal cancer, version 6.2020: featured updates to the NCCN guidelines. Journal of the National Comprehensive Cancer Network,2020,18(7):806–815
   Google Scholar
• Sartore-Bianchi A, Martino C, Lonardi S, et al. LBA35 Phase II study of pertuzumab and trastuzumab-emtansine (T-DM1) in patients with HER2-positive metastatic colorectal cancer: the HERACLES-B (HER2 Amplification for Colo-rectaL cancer Enhanced Stratification, cohort B) trial. Ann Oncol. 2019;30(Supplement_5):v869–v870.
   Google Scholar
• Strickler J, Zemla T, Ou F-S, et al. Trastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer (mCRC): initial results from the MOUNTAINEER trial. Ann Oncol. 2019;30:V200.
   Google Scholar
• Gupta R, Garrett-Mayer E, Halabi S, et al. Pertuzumab plus trastuzumab (P+ T) in patients (Pts) with colorectal cancer (CRC) with ERBB2 amplification or overexpression: results from the TAPUR Study. J Clin Oncol. 2020;38:4.
   Web of Science ®Google Scholar
• Nakamura Y, Okamoto W, Kato T, et al. 1057 - TRIUMPH: primary Efficacy of a Phase II Trial of Trastuzumab (T) and Pertuzumab (P) in Patients (pts) with Metastatic Colorectal Cancer (mCRC) with HER2 (ERBB2) Amplification (amp) in Tumor Tissue or Circulating Tumor DNA (ctDNA): a GOZILA Sub-study. Ann Oncol. 2019;30(suppl_5):v198–v252.
   Google Scholar
• Siena S, M D B, Raghav K, et al. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2021;S1470-2045(21):3–00086.
   Google Scholar
• Fakih MG. Trastuzumab Plus Pertuzumab Resistance Does Not Preclude Response to Lapatinib Plus Trastuzumab in HER2-Amplified Colorectal Cancer. Oncologist 2018;23(4):474–477.
   PubMed Web of Science ®Google Scholar
• Martinelli E, Troiani T, Sforza V, et al. Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case. ESMO Open. 2018;3(1):e000299.
   PubMed Web of Science ®Google Scholar
• Sandhu J, Wang C, Fakih M. Clinical Response to T-DM1 in HER2-Amplified, KRAS-Mutated Metastatic Colorectal Cancer[J]. Journal of the National Comprehensive Cancer Network, 2020, 18(2): 116–119
   PubMed Web of Science ®Google Scholar